Investment Thesis
Delcath demonstrates exceptional revenue growth (+129% YoY) with exceptional gross margins (85.1%), supported by a fortress balance sheet with $41.3M cash and zero debt. However, the company remains unprofitable operationally (-6.5% margin) and generates minimal free cash flow (1.1% FCF margin), indicating it is a pre-profitability medical device company requiring successful execution on operational efficiency and scale.
Strengths
- Exceptional revenue growth of 129.1% YoY indicates strong market adoption
- Exceptional gross margin of 85.1% demonstrates pricing power and product differentiation
- Fortress balance sheet with $41.3M cash, zero long-term debt, and 11.24x current ratio provides substantial runway
- Stockholders equity of $112.7M against only $12.1M liabilities shows minimal financial risk
- Recent insider activity (8 Form 4 filings in 90 days) shows management engagement
Risks
- Operating loss of $1.6M despite $25M revenue indicates company not yet operationally profitable at current scale
- Operating cash flow of only $857K (3.4% of revenue) is dangerously low relative to revenue generation
- Free cash flow of $287K is minimal and unsustainable as a business model; company must reach profitability soon
- Pre-profitability status in medical devices sector carries significant execution risk on product-market fit and regulatory approval
- Net loss of $1.1M with negative ROE/ROA indicates shareholder value destruction despite growth
Key Metrics to Watch
- Path to operating profitability: Watch for operating margin inflection toward break-even
- Operating cash flow conversion: Monitor if OCF scales with revenue (should approach 10%+ of revenue)
- Gross margin sustainability: Verify if 85% margin can be maintained at higher volumes
- Cash runway adequacy: Track quarterly burn rate relative to $41.3M cash balance
Financial Metrics
Revenue
25.0M
Net Income
-1.1M
EPS (Diluted)
$-0.03
Free Cash Flow
287.0K
Total Assets
124.8M
Cash
41.3M
Profitability Ratios
Gross Margin
85.1%
Operating Margin
-6.5%
Net Margin
-4.3%
ROE
-0.9%
ROA
-0.9%
FCF Margin
1.1%
Balance Sheet & Liquidity
Current Ratio
11.24x
Quick Ratio
10.33x
Debt/Equity
0.00x
Debt/Assets
9.7%
Interest Coverage
-0.08x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T10:19:43.726774 |
Data as of: 2026-03-31 |
Powered by Claude AI